First results of migoprotafib, a potent and highly selective Src homology-2 domain-containing phosphatase 2 (SHP2) inhibitor in patients with advanced solid tumors.
Johnson ML, Wolf BB, Wang JS, Philipovskiy A, Shapiro GI, Bockorny B, Guo W, Shen J, Jen KY, LeRose M, Hunter TL, Padval M, Schmidt-Kittler O, Bhatia N, Dubey S, Suchomel J, Bendell JC, Jauhari S, Eng-Wong J, Lin JJ.
Johnson ML, et al. Among authors: lin jj.
Mol Cancer Ther. 2024 Dec 5. doi: 10.1158/1535-7163.MCT-24-0466. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 39632729